A
Andrew R. Blight
Researcher at Acorda Therapeutics, Inc.
Publications - 92
Citations - 5541
Andrew R. Blight is an academic researcher from Acorda Therapeutics, Inc.. The author has contributed to research in topics: Spinal cord injury & Clinical trial. The author has an hindex of 32, co-authored 92 publications receiving 5042 citations.
Papers
More filters
Journal ArticleDOI
Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials
James W. Fawcett,Armin Curt,John D. Steeves,William P. Coleman,Mark H. Tuszynski,Daniel P. Lammertse,Perry F. Bartlett,Andrew R. Blight,Volker Dietz,John F. Ditunno,Bruce H. Dobkin,Leif A. Havton,P H Ellaway,Michael G. Fehlings,A Privat,Robert G. Grossman,James D. Guest,Naomi Kleitman,Masaya Nakamura,M. Gaviria,D J Short +20 more
TL;DR: The spontaneous rate of recovery after SCI and resulting consequences for achieving statistically significant results in clinical trials are examined, based on previous data of the magnitude of spontaneous recovery afterSCI, as measured by changes in ASIA motor scores.
Journal ArticleDOI
Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures
John D. Steeves,Daniel P. Lammertse,Armin Curt,James W. Fawcett,Mark H. Tuszynski,John F. Ditunno,P H Ellaway,Michael G. Fehlings,James D. Guest,Naomi Kleitman,Perry F. Bartlett,Andrew R. Blight,Volker Dietz,Bruce H. Dobkin,Robert G. Grossman,D J Short,Masaya Nakamura,William P. Coleman,M. Gaviria,A Privat +19 more
TL;DR: An international panel reviewed the methodology for clinical trials of spinal cord injury (SCI), and provided recommendations for the valid conduct of future trials, and focused on outcome measures that are relevant toclinical trials of experimental cell-based and pharmaceutical drug treatments.
Journal ArticleDOI
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Andrew D. Goodman,Theodore R Brown,Lauren B. Krupp,Randall T Schapiro,Steven R. Schwid,Ron Cohen,Lawrence Marinucci,Andrew R. Blight +7 more
TL;DR: Fampridine improved walking ability in some people with multiple sclerosis, and was associated with a reduction of patients' reported ambulatory disability, and is a clinically meaningful therapeutic benefit.
Journal ArticleDOI
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
Andrew D. Goodman,Andrew D. Goodman,Theodore R Brown,Keith R. Edwards,Lauren B. Krupp,Randall T Schapiro,Ron Cohen,Lawrence Marinucci,Andrew R. Blight +8 more
TL;DR: This phase 3 study was designed to confirm efficacy and further define safety and pharmacodynamics in multiple sclerosis patients treated with oral, extended‐release dalfampridine (4‐aminopyridine) 10mg twice daily.
Journal ArticleDOI
Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design.
Daniel P. Lammertse,Daniel P. Lammertse,Mark H. Tuszynski,Mark H. Tuszynski,John D. Steeves,Armin Curt,James W. Fawcett,C Rask,John F. Ditunno,Michael G. Fehlings,James D. Guest,P H Ellaway,Naomi Kleitman,Andrew R. Blight,Bruce H. Dobkin,Robert G. Grossman,H Katoh,A Privat,Michael W. Kalichman +18 more
TL;DR: It is imperative that the design and conduct of SCI clinical trials should meet appropriate standards of scientific inquiry to insure that meaningful conclusions about efficacy and safety can be achieved and that the interests of trial subjects are protected.